Supernus Pharmaceuticals Inc (SUPN)

Debt-to-equity ratio

		Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Long-term debt	US$ in thousands	—	—	379,252	361,751	345,170
Total stockholders’ equity	US$ in thousands	1	0	815,851	744,858	595,428
Debt-to-equity ratio		0.00	—	0.46	0.49	0.58

December 31, 2023 calculation

Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $—K ÷ $1K
= 0.00

The debt-to-equity ratio of Supernus Pharmaceuticals Inc has shown a declining trend over the past five years, decreasing from 0.58 in 2019 to 0.00 in 2023. This indicates that the company has been reducing its reliance on debt financing in relation to equity financing. A debt-to-equity ratio of 0.00 in 2023 suggests that the company has no debt on its balance sheet and is fully funding its operations through equity.

This significant decrease in the debt-to-equity ratio may indicate a stronger financial position and lower financial risk for Supernus Pharmaceuticals Inc. The company's ability to maintain a low or zero debt-to-equity ratio can be seen as a positive sign of financial stability and flexibility.

Overall, the decreasing trend in the debt-to-equity ratio of Supernus Pharmaceuticals Inc demonstrates prudent financial management and a conservative approach to financing its operations.